US2018071334A1PendingUtilityA1

Reducing the proliferation of carcinoma cells by administration of a poly-oxygenated metal hydroxide

46
Assignee: UNIV BAYLORPriority: Mar 30, 2016Filed: Oct 30, 2017Published: Mar 15, 2018
Est. expiryMar 30, 2036(~9.7 yrs left)· nominal 20-yr term from priority
Inventors:Erica D. BruceChristie SayesJohn W. Woodmansee, Jr.
A61P 7/08A61K 33/08A61K 47/6823A61K 47/60A61K 33/06A61K 47/02A61K 9/08A61K 9/0026A61K 47/6923A61K 47/6921A61K 47/48861A61K 47/48215
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A colloid or crystalline solution with the addition of poly-oxygenated metal hydroxide particles. The solution is configured to treat a condition of a mammal, including a human individual and an animal, including a depletion of hemoglobin and hemorrhagic shock. The solution can be intravenously administered. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as O×66™. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An oxygen enabled solution, comprising:
 a fluid; and   a quantity of a poly-oxygenated metal hydroxide material disposed in the fluid and forming a colloid or crystalline solution.   
     
     
         2 . The oxygen enabled solution as specified in  claim 1  wherein the poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen molecules to a mammal when administered to the mammal. 
     
     
         3 . The oxygen enabled solution as specified in  claim 2  wherein the solution is a 75-90% colloid or crystalline solution with 10-25% addition of the poly-oxygenated metal hydroxide material. 
     
     
         4 . The oxygen enabled solution as specified in  claim 3  wherein the solution is a 75-90% colloid with 10-25% addition of the poly-oxygenated metal hydroxide material. 
     
     
         5 . The oxygen enabled solution as specified in  claim 3  wherein the fluid is phosphate buffered saline (PBS). 
     
     
         6 . The oxygen enabled solution as specified in  claim 5  wherein the fluid is a lactated Ringers solution (LRS). 
     
     
         7 . The oxygen enabled solution as specified in  claim 3  wherein the solution is a 75-90% crystalline solution with 10-25% addition of the poly-oxygenated metal hydroxide material. 
     
     
         8 . The oxygen enabled solution as specified in  claim 8  wherein the fluid is phosphate buffered saline (PBS). 
     
     
         9 . The oxygen enabled solution as specified in  claim 3  wherein the solution has a concentration range of 0.1 mg/l to 1000 mg/l. 
     
     
         10 . The oxygen enabled solution as specified in  claim 1  wherein the poly-oxygenated metal hydroxide material comprises particles that are surface modified. 
     
     
         11 . The oxygen enabled solution as specified in  claim 10  wherein the poly-oxygenated metal hydroxide material comprises nano-sized particles surface modified with polyethylene glycol (PEG). 
     
     
         12 . The oxygen enabled solution as specified in  claim 11  wherein the solution is configured to resuscitate a mammal having a depletion of hemoglobin. 
     
     
         13 . The oxygen enabled solution as specified in  claim 1  wherein the solution is configured to resuscitate a mammal in hemorrhagic shock. 
     
     
         14 . The oxygen enabled solution as specified in  claim 12  wherein the solution comprises an oxygen resuscitative fluid configured to increase tissue interstitial fluid (ISF) oxygen, tension (PO 2 ) in a mammal when administered to the mammal. 
     
     
         15 . The oxygen enabled solution as specified in  claim 13  wherein the solution comprises an oxygen resuscitative fluid configured to increase tissue interstitial fluid (ISF) oxygen tension (PO 2 ) in a mammal when administered to the mammal. 
     
     
         16 . The oxygen enabled solution as specified in  claim 1  wherein the poly-oxygenated metal hydroxide material comprises a poly-oxygenated aluminum hydroxide. 
     
     
         17 . The oxygen enabled solution as specified in  claim 1  wherein the poly-oxygenated metal hydroxide material comp s particles having a diameter of less than or equal to 100 um. 
     
     
         18 . The oxygen enabled solution as specified in  claim 1  wherein the poly-oxygenated metal hydroxide material comprises particles having a diameter of less than or equal to 10 um. 
     
     
         19 . The oxygen enabled solution as specified in  claim 1  wherein the solution is configured to be administered to a mammal intravenously. 
     
     
         20 . The oxygen enabled solution as specified in  claim 1  wherein the mammal is a human individual.

Join the waitlist — get patent alerts

Track US2018071334A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.